A phase 3 study of the efficacy of Eylea injections to treat neovascular AMD has shown sustained improvement in visual acuity at 96 weeks, Regeneron Pharmaceuticals and Bayer Healthcare announced in a press release. In the first year of the parallel VIEW 1 and VIEW 2 studies, patients received Eylea (aflibercept, Regeneron Pharmaceuticals)...

Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release. Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release...

Age-related Macular Degeneration (AMD) has long been thought to be more frequent in non-Hispanic whites than in blacks in the United States. This was based on observations reported in clinical case series. The use of new AMD classification schemes and severity scales in large population-based studies has confirmed that non-Hispanic whites have...

The 4-year incidence and progression of age-related macular degeneration (AMD) in Latinos are lower than in non-Hispanic whites, according to a report from the Latino Eye Study. Latinos represent the largest of minority populations in the United States. According to the 2004 US Census, 35.6 million people, or 12.5% of the nation's residents,...

The Latino Eye Study found that ocular factors such as cataract, cataract surgery, and refractive errors associated with early age-related macular degeneration (AMD) lesions found in Latinos are consistent with those in non-Hispanic Whites. Previous population-based studies among Caucasians have identified possible associations of various...

The Latino Eye Study identified older age and higher pulse pressure as risk factors for 4-year incidence of age-related macular degeneration (AMD) in adult Latinos. Latinos constitute the largest and fastest-growing minority segment of the US population. If recent trends continue, the US Latino population is estimated to increase to 102.6...

Racial minorities, including Latinos and Asian Americans, do not appear to have similar risks of developing nonexudative and exudative Age-related macular degeneration (AMD) as whites in the United States, according to a recent study. Several large population-based studies have examined differences in the prevalence of AMD between whites and...

The long-awaited primary outcome of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) study was that patients receiving either monthly Avastin (bevacizumab) or monthly Lucentis (ranibizumab) had equivalent visual acuity at 1 year. For the majority of clinicians who already preferentially used Avastin for age-related...

The much anticipated CATT study has now been published. The National Eye Institute is to be applauded for having sponsored this landmark trial and for setting a new standard of transparency by submitting most of the raw data on the Internet. Millions of people who cannot afford Lucentis (ranibizumab) now have the benefit of a high level of...

For 5 years, patients and clinicians have wrestled with the choice between two drugs for the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF), the cytokine primarily responsible for blood-vessel growth, is inhibited when anti-VEGF drugs are injected repeatedly into the eye, and blindness is...

The authors report a cluster of 14 consecutive cases of sterile endophthalmitis occurred after intravitreal injection of Avastin (bevacizumab) obtained from a single batch that occured in Japan circa 2009. Intravitreous Avastin (IVB) can cause complications, including traumatic cataract, retinal detachment, and endophthalmitis, with the...

Elevated intraocular pressure (IOP) after an intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents for age-related macular degeneration (AMD) is not uncommon, but this study failed to identify any significant risk factors for its occurrence. Studies investigating transient increases in intraocular pressure (IOP)...